Advancing Neuroscience and Rare Disease Innovation

Catherine Owen Adams, CEO of Acadia Pharmaceuticals, discusses the advancements in neuroscience and rare disease innovation, highlighting the accelerated innovation in neuro diseases and the impact of biomarkers in phase 2 and 3 trials. She emphasizes the importance of understanding patient subtypes and the role of biomarkers in improving treatment specificity and patient outcomes. Adams also stressed the need for pharmaceutical leaders to engage in policy advocacy to navigate the evolving regulatory landscape and ensure patient-centric policies. She concluded by reiterating Acadia's mission to develop meaningful innovations for neurological disorders and rare diseases.

Highlights from the episode include:

• Catherine discusses the recent advancements in neuroscience and rare disease innovation over the past few years.
• The importance of biomarkers in understanding the heterogeneity of symptoms in neuro diseases like dementia.
• The evolving regulatory landscape and the importance of continuing with clinical trials and submissions.
• Catherine emphasizes the need for employees to feel that their ideas are heard and valued, which leads to better engagement and performance.